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Abstract
The increase in opioid prescriptions in the United States has been accompanied by an increase in misuse as well as over-
dose and toxicity related morbidity and mortality. However, the extent of the increased opioid use, including misuse in the 
United Kingdom, currently remains less debated. Recent studies in the United Kingdom have shown a rise in opioid use and 
attributed deaths, particularly in areas with higher deprivation. There are also large variations amongst the devolved nations; 
Scotland has the highest drug-related deaths and year-on-year increase within Europe. Better clinical guidelines that can 
enable person-centred management of chronic pain, medicines optimisation, and early diagnosis and treatment of opioid use 
disorder are crucial to addressing opioid-related morbidity and mortality in the United Kingdom.
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Impacts on practice
• Triangulation of currently available data from multiple 
sources confirms that opioid crisis is deepening in the 
United Kingdom which needs urgent policy and practice 
focus on patient pathways to opioid misuse.
• Clinical guidelines and innovative service models that 
can enable person-centred management of chronic pain, 
medicines optimisation, and early diagnosis and treat-
ment of opioid use disorder are needed.
• There is a need for better linkage of data across sectors 
to enable epidemiological surveillance and monitoring 
of prescribed and illicit opioids use.
Introduction
The term ‘opioid epidemic’ specifically refers to increased 
deaths and hospitalisations due to prescribed and illicit opi-
oids and their analogues. The opioid epidemic in the United 
States (US), [1] has led to calls internationally regarding 
rational prescribing and use of prescribed opioids as well 
as the need to address the misuse of illicit opioids (for 
instance, heroin and opium) and diverted pharmaceutical 
opioids (such as buprenorphine, methadone, and morphine). 
The aim of this paper is to critically discuss current practice 
and research regarding the extent of prescribed opioid use, 
particularly in the context of chronic non-malignant pain 
(CNMP) management, and identify how rising opioid (both 
prescribed and illicit use) related morbidity and mortality 
can be addressed.
Chronic opioid therapy (COT) in the management 
of CNMP
COT defined as the use of opioids on most days for more 
than three months, remains the mainstay of CNMP [2]. 
CNMP is a condition where patients persistently or recur-
rently experience pain for at least three months [3]. CNMP 
affects 20% of adults worldwide. In the United Kingdom 
(UK), studies suggest that up to half of the population (about 
28 million adults) may be living with CNMP [4]. There is, 
however, a lack of evidence of improved patient outcomes 
in relation to the use of COT in CNMP. A recent randomised 
clinical trial has shown adverse effects and notably worse 
pain intensity in opioid users compared to non-opioid 
users, with no difference in pain interference [5]. Evidence 
also suggests that discontinuing COT in CNMP does not 
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substantially reduce pain intensity [6]. COT is associated 
with various adverse effects including suicide attempts and 
polydrug use (opioids with alcohol or benzodiazepines) 
serious fractures, immunosuppression and increased risk 
for cardiovascular disease and early mortality. Adverse 
consequences of COT on the healthcare system and the 
wider society due to opioids dependence, misuse, abuse and 
addiction have also been reported [7]. The term Opioid Use 
Disorder (OUD) is often used to define the clinical implica-
tions of COT. OUD is compulsive behaviour characterised 
by consumption of more opioid or for longer than originally 
intended that leads to serious impairment or distress [8].
In addition to CNMP, prescribing of opioids for acute 
indications such as surgical pain in opioid-naïve patients 
can also lead to a transition to COT. Data show that patients 
prescribed opioids within seven days of surgery are 44% 
more likely to become COT users within a year than those 
not prescribed an opioid [9].
Trends in prescribed opioid use in the UK
Many UK based studies show an upward trend in opioid 
prescribing and use in the National Health Services (NHS) 
parallel to that in the US. In 2017–2018, 12.8% of Eng-
land’s population had an opioid prescription dispensed, with 
approximately 50% taking them for at least 1 year [10]. A 
400% rise in prescription opioids has been reported in the 
past decade in the UK [11]. Dispensing of opioids by com-
munity pharmacies increased in England from 33.1 million 
to 40.5 million between 2008 and 2018 [10].
Currently, in England, over half of drug deaths are known 
to involve an opiate [12]. Direct links between prescribing 
practices (including any potentially inappropriate prescrib-
ing) and the opioid related harm and deaths need to be fur-
ther investigated. However, the observed increase in pre-
scription opioids corresponds to increased opioid -related 
death trends. Overall, prescribed opioid associated deaths in 
England and Wales had a four-fold increase between 1993 
and 2017 [12].
There is also an increasing trend in deaths associated with 
more potent opioids such as fentanyl products. For example, 
in England fentanyl-related deaths increased from eight in 
2008 to 135 in 2017 [13]. Guidelines recommend that such 
strong opioids be prescribed for unremitting cases, spe-
cifically for short-term use only, stepping patients down to 
weaker opioids as appropriate, or withdrawing if ineffective 
[14]. However, prescribed doses are known to be too high 
and prescribed for too long. The rise in tramadol-related 
mortality combined with a rise in tramadol’s prescription 
supply [15] illustrates the link between prescribing and 
opioid-related morbidity and mortality.
Geographical variations and link with deprivation
There appear to be regional variations within the UK in the 
prevalence of opioid use and deaths. Drug use in Scotland 
is disproportionately higher than in other parts of the UK. 
Between 2017 and 2018, Scotland had 1187 -related deaths 
per million populations, three times that in England and 
Wales [16]. Regional variations in higher opioid-related 
deaths have been linked to higher deprivation, social issues, 
and the availability of street fentanyl. Inequality-associated 
social risk factors (childhood drug exposure, prison drug 
exposure, adverse childhood events, homelessness, unem-
ployment, social marginalisation, mental illness, psychologi-
cal trauma) are other linked risk factors [16, 17].
Links between deprivation and higher rates of both 
prescribed and illicit opioid use have been further demon-
strated in the published literature. Opioid prescriptions are 
nearly two times higher in areas with greater deprivation 
in England [17]. Approximately 90% of the highest opioid 
prescribing areas are located in the north of England, dem-
onstrating a strong link with deprivation [18]. The greater 
prevalence of chronic pain and lack of adequate addiction 
treatment services in socio-economically deprived areas 
may lead to suboptimal prescribing practices. In addition, 
populations in deprived areas are more likely to take these 
medicines chronically, usually alongside antidepressants, 
benzodiazepines, or gabapentinoids [8, 10].
The need for better diagnosis and linked datasets
Better use and linkage of healthcare databases are needed 
in the UK to obtain a clearer picture of the extent of both 
prescribed and illicit opioid use. There is a need to establish 
linked datasets to identify the magnitude of inappropriate 
including overprescribing, opioid abuse, diversion, adverse 
events including mortality, and underutilisation of substitu-
tion treatments for pain including CNMP and to develop 
further evidence-based approaches to addressing the prob-
lem. For instance, prescribed opioids can be obtained from 
various sources (the independent health sector and the inter-
net) but data from these sources are not integrated. In addi-
tion, there is a lack of data on the sales of over-the-counter 
(OTC) opioid-containing preparations. The lack of inte-
grated healthcare data between primary (general practice/
family physician clinics) and secondary (hospital) is also 
a barrier to treatment optimisation. For example, National 
Health Services primary care prescribers face challenges due 
to delayed or incomplete patient discharge medical records 
from hospitals. There is also a need to improve toxicologi-
cal assessments to identify causative factors for overdose 
incidents, information-sharing on drug overdose and deaths 
and establishment of useful links between national datasets, 
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including death registrations and national treatment moni-
toring systems.
Role of healthcare professionals and the need 
for person‑centred guidelines
Person-centred care enhances the patient’s involvement in 
their own care to meet their unique expectations in treat-
ment, planning, and delivery elements. Non-consideration of 
patient needs can lead to suboptimal outcomes. For example, 
in the US, the misapplication or misinterpretation of the 
Centre for Disease Control guideline on opioid prescribing 
for chronic pain led to forced opioid tapering and abandon-
ment for patients who were on COT. Many CNMP patients 
faced a significant challenge in obtaining proper care, report-
edly resulting in profound physical, emotional, and societal 
costs. Such incidents reinforce the need for patient-centred 
guidelines. Best practices in CNMP management should 
include developing an effective pain treatment plan after 
accurate evaluation to establish a diagnosis, with measurable 
outcomes that focus on improving patients’ quality of life 
(QoL), functionality, and daily living activities [19]. Also 
establishing a therapeutic alliance between patient and clini-
cian based on compassionate, empathetic care is necessary 
to counter the suffering of CNMP patients.
One way to reduce the increase in opioid use is by re-eval-
uating and leveraging the existing healthcare professionals’ 
(HCPs) roles [19]. Health professionals’ ability to balance 
CNMP treatment while minimising risks for OUD is vital 
to reduce opioid-associated morbidity and prevent overdose. 
Appropriate initiation, reduction, or discontinuation of COT 
is essential to minimise patients’ risk of psychological dis-
tress and opioid-related hospitalisation. Due to the paucity 
of essential data surrounding the best approach to support 
COT patients or to treat OUD, a single clinician is unlikely 
to have the skills to manage these patients’ needs. A multi-
disciplinary team (MDT) is needed, combining the skills of 
diverse healthcare professionals including general practition-
ers, nurses, psychiatrists, pharmacists and pain consultants, 
moulding various interventions including medications and 
non-pharmacological interventions. MDTs can successfully 
reduce prescribed opioids, therefore associated disorders and 
have been identified to have greater long term effectiveness 
than usual care in reducing pain and disability, and improv-
ing QoL and ability to return to work [19].
The National Institute of Clinical Excellence (NICE) 
in England is aiming to publish an updated guideline on 
the management of CNMP, which aims to include rational 
prescribing of opioids. However, the problem has not been 
addressed optimally as these guidelines do not clearly state 
care and support for practical daily decisions in manage-
ment. Individualised patient-centred care in the diagnosis 
and treatment of OUD related to CNMP is fundamental to 
improve the outcomes of treatment in these populations. 
Safe opioid stewardship, with regular re-evaluation of 
patient risk, is essential, which involves identifying risk fac-
tors from patient history, family history, current biopsycho-
social factors, screening and diagnostic tools, and integrated 
behavioural, complementary interventions.
Improving access to services is vital in addressing opioid 
misuse. Access is often difficult for people with dual diag-
noses of mental health problems and substance misuse and 
vulnerable groups such as the homeless populations [20, 21]. 
Therefore, primary care providers, particularly community 
pharmacists, play a vital role in facilitating accessibility. 
Patients presenting with a significant level of psychologi-
cal, physical and/or socio-professional problems should be 
referred promptly to the appropriate service. Patients who 
repeatedly struggle with opioid abuse often end up home-
less/imprisoned, less capable or motivated to improve their 
health because of their other life priorities [22, 23]. Health-
care professionals, including community pharmacists, must 
be supported in managing patients’ clinical and social needs, 
using innovative service models such as social prescribing 
[23, 24].
Many patients may find perceived stigma (disgrace, 
humiliation) and discrimination in healthcare settings as 
barriers to seeking treatment or optimising existing treat-
ment for CNMP and may end up abusing opioids. As many 
patients who misuse prescribed medications often do not 
join the ‘typical’ subculture of illicit users (i.e. social ele-
ments associated with illicit drug consumption such as street 
consumption, socialising publicly with other illicit users) or/
and do not seek help from addiction treatment services, their 
problems often go unrecognised and untreated [25]. In addi-
tion, numerous opioid-dependent individuals seek advice 
from the internet, rather than their HCP, often accessing 
unreliable source of information.
Conclusion
Suboptimal management of CNMP remains one of the key 
issues linked to the rising trend in opioid prescribing in the 
UK. Evidence from research literature and UK national 
statistics suggests that such rising trends correspond to 
increasing opioid related harms and deaths. Opioid-related 
deaths are more prevalent in deprived areas with the North 
of England and Scotland in particular facing more signifi-
cant problems. Better linkage of data across care sectors 
will enable enhanced epidemiological surveillance and 
monitoring to target the rising opioid-related morbidity and 
mortality and identify the extent of the contribution made 
by prescribed and illicit opioids use. There is an urge to 
enable healthcare professionals to manage CNMP better as 
well as to prevent, detect, and address OUD earlier. These 
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could be achieved through better education and awareness 
of OUD, development of person-centred guidelines and a 
MDT approach combining pharmacological and evidence 
based non-pharmacological interventions. A comprehensive 
approach to manage the changing needs of CNMP patients 
will help them to achieve functional recovery, autonomy, 
and improved quality of life, preventing negative outcomes 
from their treatment.
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